Robert Pirker
About
In The Last Decade
Robert Pirker
242 papers receiving 11.3k citations
Hit Papers
Peers
Comparison fields: 5 of 135
- Oncology 7.4k
- Pulmonary and Respiratory Medicine 5.4k
- Molecular Biology 3.8k
- Cancer Research 1.9k
- Surgery 1.2k
Countries citing papers authored by Robert Pirker
This map shows the geographic impact of Robert Pirker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Pirker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Pirker more than expected).
Fields of papers citing papers by Robert Pirker
This network shows the impact of papers produced by Robert Pirker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Pirker. The network helps show where Robert Pirker may publish in the future.
Co-authorship network of co-authors of Robert Pirker
This figure shows the co-authorship network connecting the top 25 collaborators of Robert Pirker. A scholar is included among the top collaborators of Robert Pirker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Pirker. Robert Pirker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 77 | |
| 3 | 5 | |
| 4 | Epidermal Growth Factor Receptor Mutation-PositiveNon-Small-Cell Lung Cancer in the Real-World Setting in CentralEurope The INSIGHT Study | 1 |
| 5 | EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study breakdown → | 453 |
| 6 | 218 | |
| 7 | 57 | |
| 8 | 66 | |
| 9 | 8 | |
| 10 | Expression of the lung resistance protein in primary colorectal carcinomas. | 3 |
| 11 | P-glycoprotein and MRP1 expression in axillary lymph node metastases of breast cancer patients. | 33 |
| 12 | 5 | |
| 13 | Expression of the lung resistance protein (LRP) in primary breast cancer. | 18 |
| 14 | Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma. | 39 |
| 15 | 42 | |
| 16 | 29 | |
| 17 | 0 | |
| 18 | 28 | |
| 19 | Clinical relevance of drug resistance genes in malignant disease. | 22 |
| 20 | 10 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.